DTIL
Precision·NASDAQ
--
--(--)
--
--(--)
DTIL Profile
Precision Biosciences, Inc.
A clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies
Biological Technology
--
03/28/2019
NASDAQ Stock Exchange
68
12-31
Common stock
302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701
--
Precision BioSciences, Inc., was incorporated in Delaware in January 2006. The company is a clinical-stage gene-editing company developing in vivo gene-editing therapies using its proprietary ARCUS platform. Designed for complex editing such as gene insertion, elimination and excision, its platform leverages its unique cutting properties and smaller size to achieve clear therapeutic outcomes.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
